Repurposed drugs offer no sustained benefit for long COVID fatigue - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Repurposed drugs offer no sustained benefit for long COVID fatigue

Colchicine and famotidine-loratadine modestly reduced fatigue during 12 weeks of treatment, but the differences disappeared after the drugs were stopped.

  • By

  • Alun Evans

  • August 10, 2026

  • 4 min

Share

Original Source(s)

Repurposed drugs offer no sustained benefit for long COVID fatigue

  • by Alun Evans

  • August 10, 2026

Related Content

Beyond Functional Independence: Symptom Burden and Emotional Difficulties in Pediatric Long COVID — A Cross-Sectional Exploratory Study

Case Report: Mitochondrial insufficiency underlies cholinergic failure in post-vaccination long COVID: a candidate treatment protocol

Pathogen effects on the brain: the case of SARS-CoV-2 spike protein and neuro COVID